Dabid Under the Microscope: Dr Abidi Pharmaceutical's Six-Month Profit Jumped 3.3x; Dissecting a Surge That Didn't Come From Sales Alone (Saturday, 18 July 2026)

Dr Abidi Pharmaceutical's six-month profit jumped three point three times, but not from sales alone. Today, Saturday July eighteenth, the company released its half-year report mid-session. Net profit reached five thousand two hundred fifty-seven billion tomans, three point three times last year. The fiscal year ends in Azar, so this is the halfway mark, and it is still unaudited. A look at the core numbers: revenue, gross, operating and net profit all more than doubled. The operating margin jumped from about forty-two to fifty percent, unusually high for a drugmaker. Revenue grew one hundred eighteen percent, but part of that is inflation, not more units sold. Admin costs rose only sixty-two percent, half the pace of sales; that leverage magnified profit. About nine hundred fifty-eight billion tomans of non-operating income also helped; its repeatability is unclear. With a market cap of one hundred seven thousand billion tomans, the price is about twenty times this half-year profit. Three questions stay open: the cash backing of profit, price versus volume, and the non-operating income. The real test is whether that fifty percent margin holds in the second half of the year. Financial costs reached one thousand two hundred seventy-five billion tomans, about a fifth of operating profit. Watch the cash-flow statement, the price-versus-volume split, and the audited version. Full analysis on Sahmino.com. Do you think that fifty percent margin lasts, or is it a passing peak? Comment below.